Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price increased by Stifel Nicolaus from $74.00 to $77.00 in a research note published on Wednesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other brokerages also recently issued reports on RARE. JPMorgan Chase reiterated an overweight rating and set a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Saturday, January 6th. Finally, Wedbush restated a positive rating and issued a $71.00 price target (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $69.76.
Shares of Ultragenyx Pharmaceutical stock opened at $54.26 on Wednesday. Ultragenyx Pharmaceutical has a 12-month low of $41.67 and a 12-month high of $71.99.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.00) by ($0.27). The business had revenue of $2.41 million for the quarter, compared to analysts’ expectations of $0.75 million. During the same quarter last year, the firm earned ($1.75) EPS. equities analysts forecast that Ultragenyx Pharmaceutical will post -5.99 earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Ladenburg Thalmann Financial Services Inc. raised its holdings in Ultragenyx Pharmaceutical by 1,246.9% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,273 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 3,030 shares during the last quarter. SG Americas Securities LLC bought a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at approximately $156,000. Xact Kapitalforvaltning AB bought a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $205,000. B. Riley Financial Inc. bought a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $213,000. Finally, Aperio Group LLC bought a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $254,000. Institutional investors and hedge funds own 87.19% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Ultragenyx Pharmaceutical (RARE) Given New $77.00 Price Target at Stifel Nicolaus” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/21/ultragenyx-pharmaceutical-rare-given-new-77-00-price-target-at-stifel-nicolaus.html.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.